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Patients with cystic ﬁbrosis (PWCF) are typically prescribed high calorie, high fat
diets. With improved survival, there is emerging data that suggests an increased
risk of cardiovascular disease. This study examines the prevalence of dyslipidaemia
and its associated clinical phenotype in an Irish adult CF population.
Biometric data and fasting lipid proﬁles were collected from patients attending
annual assessment at the CF day unit between August 2012 and August 2013.
Phenotypic information was collected from patient charts.
98 participants (mean age 28±10) were included in the study. Of this sample,
31% had CF-related diabetes and 83% were pancreatic insufﬁcient. Across the
population, mean and median lipid proﬁles were normal. However, 25% had lower
HDL, 17% had elevated triglycerides, 17% elevated LDL, and 8% elevated total
cholesterol. Total cholesterol and LDL were found to increase with increasing age
and BMI. Increased total cholesterol was strongly correlated with increased LDL.
On subgroup analysis, pancreatic sufﬁcient subjects were more likely to have higher
LDL (p< 0.001) and 63% of these had higher than optimal LDL. Diabetics were
more likely to have higher triglycerides (p< 0.05) and 29% had higher than optimal
levels. Men were found to have lower total cholesterol (p = 0.007) and lower HDL
(p = 0.001).
With increasing age, dyslipidaemia is an important emerging cardiovascular risk
factor for PWCF. This is the ﬁrst study to show this in a European population and
is in keeping with previous studies.
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Vitamin A deﬁciency (VAD) has been described in cystic ﬁbrosis (CF). A Cochrane
Review (2012) suggested that there was insufﬁcient data to draw any conclusions
about the beneﬁts of vitamin A supplementation in CF. To date, only one paediatric
case report has addressed VAD in an Irish CF population.
This quantitative study was a combination of a retrospective medical record review
from January 2010 to December 2012, and a cross-sectional questionnaire-based
study of adult CF patients.
One hundred patients were included. In 2012, 8% (n = 8) were VAD (serum
retinol <0.7mmol/L) and 17% (n = 17) were insufﬁcient in vitamin A (serum
retinol 0.7–1.05mmol/L). In 2011 and 2010, 8% (n = 8) and 9% (n = 9) were VAD
respectively. There was no association between VAD and zinc deﬁciency, liver
disease, retinol-binding protein deﬁciency or markers of CF clinical phenotype.
83% (n = 83) were on multi-vitamin supplementation, including vitamin A.
The questionnaire response rate was 51% (n = 51); none of these were VAD. 23.5%
(n = 12) reported ocular symptoms; of those, three patients were insufﬁcient in
vitamin A. 5.9% (n = 3) reported night blindness. 17.64% (n = 9) had mild/moderate
conjunctival xerosis.
The prevalence of VAD in Irish adult CF patients is low when compared to inter-
national studies. This validates the role of multi-disciplinary teams and designated
CF centres in Ireland. Three of the twelve patients reporting ocular symptoms were
insufﬁcient in vitamin A. Based on ocular questionnaire results to date, there is no
clear relationship between ocular symptoms and VAD in CF.
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Objectives: Pancreatic insufﬁcient CF patients receive vitamin A supplementation
according to CF-speciﬁc recommendations. Whether current recommendations are
optimal for preventing both deﬁciency and toxicity is a subject of debate. We
studied retrospectively the vitamin A intake, serum retinol levels and coefﬁcient of
fat absorption (CFA) in paediatric CF patients during a six-year follow up period.
Methods: We included patients who had at least one measurement of both
vitamin A intake and serum retinol level and who were receiving pancreatic enzyme
replacement therapy. Dietary vitamin A intake, collected through 3-day dietary food
records, prescribed supplementation and total vitamin A intake (dietary vitamin A
plus prescribed supplementation), expressed as both % of recommended daily
advice and % of tolerable upper intake level (TUL) were described. Serum retinol
level and CFA were also examined. The cross sectional and longitudinal relations
between vitamin A intake, serum retinol level and CFA were assessed.
Results: A total of 761 measurements of both vitamin A intake and serum retinol
levels in 216 patients, and 578 CFA measurements in 191 patients were obtained.
The dietary vitamin A intake exceeded the TUL in 30% of the assessments, mainly
up to six years of age. Although patients often did not meet the CF-speciﬁc
recommendations, serum retinol deﬁciency was rare. Serum retinol levels were
not associated with total vitamin A intake or with CFA.
Conclusion: Serum retinol deﬁciency is rare despite lower than recommended
intake. However, the TUL is commonly exceeded. A reduction in CF-speciﬁc
vitamin A supplementation recommendations might be considered.
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Objectives: The prevalence of vitamin D3 (VD3) deﬁciency in cystic ﬁbrosis
(CF) patients is greater than in the general population. VD3 plays an important
role in respiratory health including the risk for chronic rhinosinusitis and nasal
polyposis. We hypothesized that cystic ﬁbrosis patients with VD3 deﬁciency are
more susceptible to nasal polyps formation.
Methods: 41 CF patients (43.6% men, 56.4% women, mean age 21±17 years)
had serum VD3 levels prospectively measured. 13 CF patients had nasal polyposis
(CFwNP) and 28 were patients without nasal polyposis (CFnonNP). 18 patients
with idiopathic nasal polyposis (INP) were used as control. Plasma levels of VD3
were measured by enzyme-linked immunosorbent. VD3 insufﬁciency was deﬁned
as <32 ng/ml and deﬁciency as <20 ng/ml.
Results: VD3 levels (ng/mL± SD) were signiﬁcantly lower in patients with CFwNP
(21.4±5.7) than in those with CFnonNP (28.8±6.2; p< 0.001). VD3 levels (ng/mL
± SD) between CFnonNP group (28.8±6.2) and INP group (30.2±4.2; p< 0.01)
were not statistically different. In the CFwNP group of patients 80% were VD3
whereas only 40% were found deﬁcient in the INP [IRR 2.03 (1.30 to 4.52),
p = 0.005]. Mean %FEV1 (% ±SD) in CFnonNP patients (88±6) was signiﬁcantly
better than in the CFwNP group (50.2±4.2; p< 0.005).
Conclusion: Low VD3 levels in CF patients are associated with increased incidence
of nasal polyps. These results suggest a role for vitamin D3 as a key player in
the immunopathology of nasal polyposis. However there are other factors of the
respiratory function in CF that affect the risk for nasal polyposis.
